Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
You also need a fulfillment tracking pipeline so patients can follow their order from compounding to quality check to shipment
Heres how they differ: 96373 Intra-arterial injection 96374 Intravenous push (not infusion) 96375 IV push with concurrent infusion 96365 Initial IV infusion, up to 1 hour Use 96372 only when no IV access is used and the administration is IM or SQ
This injectable solution is intended to support the bodys ability to convert fats and sugars into energy and may contribute to improved metabolic efficiency
Semaglutide typically produces more dramatic total weight loss but includes muscle and water loss along with fat, whereas AOD-9604 more selectively targets fat tissue
A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007
This makes it a useful tool for researchers studying: Regulation of adipose tissue metabolism Energy balance and obesity-related pathways Joint and cartilage biology in osteoarthritis models Metabolic factors associated with cardiovascular and systemic syndromes In animal studies, AOD9604 has been reported to stimulate lipolysis and inhibit lipogenesis under specific experimental conditions, providing a platform to dissect signaling mechanisms involved in fat turnover and metabolic control
US$ 21.79
US$ 22.61
US$ 29.07
US$ 25.40
US$ 22.79
